New Wound Care Gel Enters Final Stage of Study
A new therapy called Aurix promises to improve tissue regrowth for painful ulcers.
Perhaps of all the many recent advancements in the wound care industry, there is one trend that’s proved most intriguing. Over the last few years, a number of research teams have created advanced solutions for wound healing with material taken directly from the patient.
For instance, one scientist from Lehigh University is using skin cells to help create longer lasting grafts. At the same time, a team from Michigan created a special mix of polymer and stem cells to regrow bones. Doctors in China have even found stem cells in skin appendages, and that will lead to new therapies to help with chronic wounds.
Today, another important solution takes a huge step from research to approval for wide-scale use.
Nearing the finish line
As the Niagara Gazette reported, doctors from the Wound Center of Niagara at Niagara Falls Memorial Medical Center were recently awarded a multi-year study to test an essential new wound care treatment. The study, which officially began in January 2017, will center-around Aurix Therapy.
Developed by a group of scientists representing several companies and research collectives, Aurix is described as a biodynamic hematogel. The solution is created using a series of specialized compounds mixed with the plasma and blood platelets taken from the patient. It’s applied topically and meant to bolster the process of new tissue regrowth.
While there are already products involving this development of new tissue – including a topical film developed by a group from the American Association of Pharmaceutical Scientists – this is one of the first to use elements directly from the patient. Aurix has already been used in some early clinical trials and even has approval by the Food and Drug Administration. However, the study at the Niagara Wound Center is one of the final steps before Aurix can be used nationwide.
The study will focus on the safety and effectiveness of Aurix as it’s used to treat injuries like venous and pressure ulcers. So, how has Aurix faired in previous trials? According to a series of case studies culled from several research outlets, Aurix has had some noticeable success. That includes healing some wounds in just 15 days and reducing the surface area of others wounds by nearly 60 percent. Dr. Michael Mitchell is the Wound Center of Niagara’s medical director.
Speaking with the Niagara Gazette, he explained that the center is optimistic about the study and its impact on patients’ wounds.
“We are excited to have been selected to take part in this pragmatic approach to studying the potential benefits to Medicare beneficiaries of a promising treatment option,” he said. “Clinical results have shown Aurix Therapy to be safe and effective, and we are pleased to be able to offer it to qualifying Medicare patients here in Niagara.”
For all your specialized wound care products, turn to Advanced Tissue. The company delivers to both homes and long-term care facilities.